WallStreetZenWallStreetZen

NYSE: CRL
Charles River Laboratories International Inc Stock Forecast, Predictions & Price Target

Open Broker Account
OverviewForecast
EarningsDividendOwnership

Analyst price target for CRL

Based on 10 analysts offering 12 month price targets for Charles River Laboratories International Inc.
Min Forecast
$240.00+21.95%
Avg Forecast
$326.20+65.75%
Max Forecast
$430.00+118.5%

Should I buy or sell CRL stock?

Based on 11 analysts offering ratings for Charles River Laboratories International Inc.
Strong Buy
Strong Buy
8 analysts 72.73%
Buy
1 analysts 9.09%
Hold
2 analysts 18.18%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CRL stock forecasts and price targets.

CRL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Jefferies
Top 3%
98
Strong BuyUpgrades$240.00+21.95%2022-09-30
Credit Suisse
Bottom 14%
14
BuyInitiates Coverage On$285.00+44.82%2022-08-25
Wells Fargo
Bottom 22%
22
Strong BuyMaintains$300.00+52.44%2022-08-16
Morgan Stanley
Bottom 7%
7
HoldDowngrades$250.00+27.03%2022-08-04
Deutsche Bank
Bottom 26%
26
Strong BuyMaintains$290.00+47.36%2022-07-14
Guggenheim
Top 6%
95
HoldInitiates Coverage OnN/AN/A2022-05-24
Anonymous
Morgan Stanley
Strong BuyMaintains$350.00+77.85%2022-05-05
KeyBanc
Top 14%
87
Strong BuyMaintains$300.00+52.44%2022-05-05
Stephens & Co.
Bottom 13%
13
Strong BuyInitiates Coverage On$377.00+91.57%2022-04-07
Citigroup
Top 5%
96
Strong BuyUpgrades$400.00+103.25%2022-02-17

1 of 2

Forecast return on equity

Is CRL forecast to generate an efficient return?
Company
30.28%
Industry
59.3%
Market
121.74%
CRL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CRL forecast to generate an efficient return on assets?
Company
10.65%
Industry
13.85%
CRL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CRL earnings per share forecast

What is CRL's earnings per share in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$10.78+22.92%
Avg 2 year Forecast
$12.38+41.16%
Avg 3 year Forecast
$14.51+65.45%
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

CRL revenue forecast

What is CRL's revenue in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$3.9B+5.55%
Avg 2 year Forecast
$4.2B+15.2%
Avg 3 year Forecast
$4.7B+27.62%
CRL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CRL earnings growth forecast

How is CRL forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
17.94%
Industry
25.51%
Market
16.88%
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

CRL revenue growth forecast

How is CRL forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
8.32%
Industry
8.25%
Market
8.59%
CRL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CRL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CRL vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
CRL$196.80$326.20+65.75%Strong Buy
QGEN$41.28$60.00+45.35%Buy
PHG$15.39N/AN/ABuy
EXAS$32.49$67.70+108.37%Buy
DGX$122.69$147.36+20.11%Hold
View Top Diagnostic & Research Stocks

Charles River Laboratories International Stock Forecast FAQ

Is Charles River Laboratories International Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 11 Wall Street analysts covering (NYSE: CRL) stock is to Strong Buy CRL stock.

Out of 11 analysts, 8 (72.73%) are recommending CRL as a Strong Buy, 1 (9.09%) are recommending CRL as a Buy, 2 (18.18%) are recommending CRL as a Hold, 0 (0%) are recommending CRL as a Sell, and 0 (0%) are recommending CRL as a Strong Sell.

If you're new to stock investing, here's how to buy Charles River Laboratories International stock.

What is CRL's earnings growth forecast for 2022-2024?

(NYSE: CRL) Charles River Laboratories International's forecast annual earnings growth rate of 17.94% is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 25.51%, and while it is forecast to beat the US market's average forecast earnings growth rate of 16.88%.

Charles River Laboratories International's earnings in 2022 is $443,347,000.On average, 6 Wall Street analysts forecast CRL's earnings for 2022 to be $548,306,449, with the lowest CRL earnings forecast at $545,763,284, and the highest CRL earnings forecast at $552,884,147. On average, 8 Wall Street analysts forecast CRL's earnings for 2023 to be $629,687,741, with the lowest CRL earnings forecast at $584,928,031, and the highest CRL earnings forecast at $668,852,487.

In 2024, CRL is forecast to generate $738,026,585 in earnings, with the lowest earnings forecast at $698,861,838 and the highest earnings forecast at $787,872,625.

What is CRL's revenue growth forecast for 2022-2024?

(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 8.32% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.59%.

Charles River Laboratories International's revenue in 2022 is $3,688,047,000.On average, 6 Wall Street analysts forecast CRL's revenue for 2022 to be $198,006,632,497, with the lowest CRL revenue forecast at $196,189,947,760, and the highest CRL revenue forecast at $199,186,305,176. On average, 6 Wall Street analysts forecast CRL's revenue for 2023 to be $216,103,135,904, with the lowest CRL revenue forecast at $211,120,871,530, and the highest CRL revenue forecast at $220,509,424,190.

In 2024, CRL is forecast to generate $239,405,600,510 in revenue, with the lowest revenue forecast at $234,401,515,777 and the highest revenue forecast at $243,917,938,790.

What is CRL's forecast return on assets (ROA) for 2022-2025?

(NYSE: CRL) forecast ROA is 10.65%, which is lower than the forecast US Diagnostics & Research industry average of 13.85%.

What is CRL's Price Target?

According to 10 Wall Street analysts that have issued a 1 year CRL price target, the average CRL price target is $326.20, with the highest CRL stock price forecast at $430.00 and the lowest CRL stock price forecast at $240.00.

On average, Wall Street analysts predict that Charles River Laboratories International's share price could reach $326.20 by Sep 30, 2023. The average Charles River Laboratories International stock price prediction forecasts a potential upside of 65.75% from the current CRL share price of $196.80.

What is CRL's Earnings Per Share (EPS) forecast for 2022-2024?

(NYSE: CRL) Charles River Laboratories International's current Earnings Per Share (EPS) is $8.77. On average, analysts forecast that CRL's EPS will be $10.78 for 2022, with the lowest EPS forecast at $10.73, and the highest EPS forecast at $10.87. On average, analysts forecast that CRL's EPS will be $12.38 for 2023, with the lowest EPS forecast at $11.50, and the highest EPS forecast at $13.15. In 2024, CRL's EPS is forecast to hit $14.51 (min: $13.74, max: $15.49).

What is CRL's forecast return on equity (ROE) for 2022-2025?

(NYSE: CRL) forecast ROE is 30.28%, which is considered strong.
©2022 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContact
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market Industries
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.